株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

次世代癌診断市場の予測 (2017-2027年):次世代シーケンシング(NGS)、マイクロアレイ、循環腫瘍細胞 (CTC) 分析、In Situハイブリダイゼーション(ISH)、高度PCR技術

Next-Generation Cancer Diagnostics Market Forecast 2017-2027: Next-Generation Sequencing (NGS), Microarray, Circulating Tumour Cells (CTCs) Analysis, In Situ Hybridization (ISH), Advanced PCR Techniques

発行 Visiongain Ltd 商品コード 336178
出版日 ページ情報 英文 166 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=153.37円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
次世代癌診断市場の予測 (2017-2027年):次世代シーケンシング(NGS)、マイクロアレイ、循環腫瘍細胞 (CTC) 分析、In Situハイブリダイゼーション(ISH)、高度PCR技術 Next-Generation Cancer Diagnostics Market Forecast 2017-2027: Next-Generation Sequencing (NGS), Microarray, Circulating Tumour Cells (CTCs) Analysis, In Situ Hybridization (ISH), Advanced PCR Techniques
出版日: 2017年05月10日 ページ情報: 英文 166 Pages
概要

次世代癌診断の世界市場は、調査期間前半は16.5%、後半は19.1%の複合年間成長率 (CAGR) で拡大し、2016年の19億米ドルから2021年までに41億米ドル規模に成長することが見込まれています。

当レポートでは、世界の次世代癌診断市場について調査し、癌診断の手法および技術の種類と概要、市場全体の主要動向および成長見通し、検査/技術区分・地域/主要国別の動向と市場規模の推移と予測、主要企業のプロファイル、製品、取り組み、SWOT分析などをまとめています。

第1章 レポート概要

第2章 次世代癌診断の概要

  • 癌とは
  • 癌診断の概要
    • スクリーニング
    • 診断
    • ステージング
  • 癌診断の手法
    • 身体検査
    • 画像技術
    • 組織病理学的 ・細胞学的検査
    • 免疫組織化学 (IHC) 分析
    • 循環腫瘍細胞 (CTC) 分析
    • 分子診断・IVD
  • 遺伝性・後天性遺伝子突然変異検査
  • コンパニオン診断 (CDx)
  • 薬事未承認検査 (LDT:Laboratory Developed Test)
  • プレシジョンメディシン (Precision Medicine)
  • 政府による法規制
    • 米国
    • EU
  • 市場の定義

第3章 世界の次世代癌診断市場の予測

  • 世界の次世代癌診断市場:概要
  • 世界の次世代癌診断市場の予測
  • 部門別シェアの推移の予測
  • バイオマーカー・分子診断
    • 乳癌
    • 前立腺癌
    • 直腸癌
  • コンパニオン診断と2つの産業のコラボレーション
  • 承認済み検査に置き換えられるLDT
  • 診断検査の分散化
  • 次世代癌診断:成長推進因子・阻害因子

第4章 次世代癌診断の2次市場

  • 先進PCR技術
    • 市場予測
    • リアルタイムPCR市場の主要製品
    • デジタルPCR市場の主要製品
    • PCRアッセイに置き換えられるパップテスト
    • 成長推進因子・阻害因子
  • In Situハイブリダイゼーション (ISH)
    • 市場予測
    • ISH癌診断市場の主要製品
    • 乳癌のHER2検査
    • 成長推進因子・阻害因子
  • 循環腫瘍細胞 (CTC) 分析
    • 市場予測
    • 循環腫瘍細胞 (CTC)分析市場の主要製品
    • Epic Sciences・LabCorp:アジア市場での拡張
    • CTCの超音波による分離
    • CTCクラスター:転移の原因に?
    • 成長推進因子・阻害因子
  • マイクロアレイ
    • 市場予測
    • マイクロアレイ市場の主要製品
    • 動向・開発状況
    • 成長推進因子・阻害因子
  • 次世代シーケンシング (NGS)
    • 市場予測
    • 次世代シーケンシング (NGS) 市場の主要製品
    • 動向・開発状況
    • 成長推進因子・阻害因子

第5章 主要国市場の予測

  • 世界の次世代癌診断市場の予測:地域別
  • 米国
  • EU5カ国
    • ドイツ
    • フランス
    • 英国
    • スペイン
    • イタリア
  • 日本
  • 中国
  • インド
  • ブラジル
  • ロシア

第6章 主要企業

  • Roche Diagnostics
  • Abbott Laboratories
  • Qiagen
  • Thermo Fisher Scientific
  • Agilent Technologies
  • Hologic
  • Illumina
  • Myriad Genetics

第7章 定性分析・予測

  • SWOT分析

第8章 総論

  • 世界の次世代癌診断市場
  • 次世代癌診断の将来

用語集

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: PHA0192

The next-generation cancer diagnostics market is expected to grow at a CAGR of 16.5% in the first half of the forecast period and CAGR of 19.1% in the second half of the forecast period. The market is estimated at $1.9bn in 2016 and $4.1bn in 2021.

While the number of new cancer cases is expected to reach 24 million by 2035, the cost savings that could be achieved with early diagnosis will be the main driver for the market. Advances in molecular biology will also help expand the cancer diagnostics test menu.

Companion cancer diagnostics can be costly but we expect them to be increasingly adopted, particularly when choosing expensive cancer therapies. Laboratory automation, standardised commercial cancer tests and affordable benchtop instruments will continue to reduce the costs of molecular testing.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 166-page report you will receive 87 charts - all unavailable elsewhere.

The 166-page report provides clear detailed insight into the next-generation cancer diagnostics market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

  • Forecasts and analysis of the next-generation cancer diagnostics market from 2017 to 2027.
  • 5 next-generation cancer diagnostics submarkets forecast and analysis from 2017 to 2027:
    • Advanced PCR Techniques
    • In Situ Hybridization (ISH)
    • Circulating Tumour Cells (CTCs) Analysis
    • Microarray
    • Next-Generation Sequencing (NGS)
  • Revenue forecasts for 8 leading national or regional next-generation cancer diagnostics market from 2017 to 2027:
    • US
    • EU5
    • Japan
    • China
    • India
    • Brazil
    • Russia
    • Rest of the World
  • Assessment of selected leading companies marketing next-generation cancer diagnostics, examining recent performance and outlooks:
    • Roche Diagnostics
    • Abbott Laboratories
    • Qiagen
    • Thermo Fisher Scientific
    • Agilent Technologies
    • Hologic
    • Illumina
    • Myriad Genetics
  • SWOT analysis of the next-generation cancer diagnostics market, and discusses some current trends.

Visiongain's study is intended for anyone requiring commercial analyses for the next-generation cancer diagnostics market. You find data, trends and predictions.

Buy our report today Next-Generation Cancer Diagnostics Market Forecast 2017-2027: Next-Generation Sequencing (NGS), Microarray, Circulating Tumour Cells (CTCs) Analysis, In Situ Hybridization (ISH), Advanced PCR Techniques.

visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Overview of Findings
  • 1.2. Structure of the Report
  • 1.3. Global Next-Generation Cancer Diagnostics Market Segmentation
  • 1.4. Why You Should Read This Report
  • 1.5. How This Report Delivers
  • 1.6. Key Questions Answered by This Analytical Report
  • 1.7. Who is This Report For?
  • 1.8. Methodology
  • 1.9. Frequently Asked Questions (FAQ)
  • 1.10. Associated Visiongain Reports
  • 1.11. About Visiongain

2. Introduction to Next-Generation Cancer Diagnostics

  • 2.1. What Is Cancer?
  • 2.2. Cancer Diagnostics: An Overview
    • 2.2.1. Screening
    • 2.2.2. Diagnosis
    • 2.2.3. Staging
  • 2.3. Cancer Diagnosis Methods
    • 2.3.1. Physical Examination
    • 2.3.2. Imaging Techniques
    • 2.3.3. Histopathological and Cytological Techniques
    • 2.3.4. Immunohistochemistry (IHC) Analysis
    • 2.3.5. Circulating Tumour Cell (CTC) Analysis
    • 2.3.6. Molecular Diagnostics and IVD
  • 2.4. Tests for Inherited and Acquired Genetic Mutations
  • 2.5. Companion Diagnostics (CDx)
  • 2.6. Laboratory Developed Test (LDT)
  • 2.7. Precision Medicine
  • 2.8. Government Regulations
    • 2.8.1. The US Approval and Regulation System
    • 2.8.2. The EU Approval and Regulation System
  • 2.9. Market Definition

3. Next-Generation Cancer Diagnostics: World Market 2016-2027

  • 3.1. The Global Next-Generation Cancer Diagnostics Market: Overview
  • 3.2. The Global Next-Generation Cancer Diagnostics Market Forecast 2016-2027
  • 3.3. How Will Segmental Market Shares Change to 2027?
  • 3.4. Biomarkers and Molecular Diagnostics
    • 3.4.1. Biomarkers and Diagnostic Tests for Breast Cancer
    • 3.4.2. Biomarkers and Diagnostic Tests for Prostate Cancer
    • 3.4.3. Biomarkers and Diagnostic Tests for Colorectal Cancer
  • 3.5. Companion Diagnostics and Collaborations between Two Industries
  • 3.6. LDTs to be Replaced by Approved Tests
  • 3.7. Decentralisation of Diagnostic Tests
  • 3.8. Next-Generation Cancer Diagnostics: Drivers and Restraints 2017-2027

4. Next-Generation Cancer Diagnostics Submarkets 2017-2027

  • 4.1. Advanced PCR Techniques
    • 4.1.1. Advanced PCR Techniques Market Forecast 2016-2027
    • 4.1.2. Leading Products in the Real-Time PCR Market
    • 4.1.3. Leading Products in the Digital PCR Market
    • 4.1.4. Pap Tests Being Replaced by PCR Assays
    • 4.1.5. Advanced PCR-Based Techniques: Drivers and Restraints 2017-2027
  • 4.2. In Situ Hybridization (ISH)
    • 4.2.1. ISH Cancer Diagnostics Market Forecast 2016-2027
    • 4.2.2. Leading Products in the ISH Cancer Diagnostics Market
    • 4.2.3. HER2 Tests for Breast Cancer
    • 4.2.4. ISH Cancer Diagnostics: Drivers and Restraints 2017-2027
  • 4.3. Circulating Tumour Cells (CTCs) Analysis
    • 4.3.1. CTCs Analysis Market Forecast 2016-2027
    • 4.3.2. Leading Product in the CTCs Analysis Market
    • 4.3.3. Epic Sciences and LabCorp to Expand in Asia Markets
    • 4.3.4. CTCs Separation by Ultrasound
    • 4.3.5. CTC Clusters More Likely to Cause Metastasis?
    • 4.3.6. CTCs Analysis: Drivers and Restraints 2017-2027
  • 4.4. Microarray
    • 4.4.1. Microarray Cancer Diagnostics Market Forecast 2016-2027
    • 4.4.2. Leading Products in the Microarray Market
    • 4.4.3. Microarray Cancer Diagnostics: Trends and Developments
    • 4.4.4. Microarray Cancer Diagnostics: Drivers and Restraints 2017-2027
  • 4.5. Next-Generation Sequencing (NGS)
    • 4.5.1. NGS Cancer Diagnostics Market Forecast 2016-2027
    • 4.5.2. Leading Products in the NGS Market
    • 4.5.3. NGS Cancer Diagnostics: Trends and Developments
    • 4.5.4. NGS Cancer Diagnostics: Drivers and Restraints 2017-2027

5. Leading National Markets 2017-2027

  • 5.1. World Next-Generation Cancer Diagnostics Market: Regional Forecast 2017-2027
    • 5.1.1. How Will Regional Market Shares Change to 2027?
  • 5.2. US Next-Generation Cancer Diagnostics Market Forecast 2017-2027
    • 5.2.1. FDA Provides Guidance for Molecular Diagnostic Instruments with Combined Functions
    • 5.2.2. Obama Launched 'Precision Medicine Initiative'
  • 5.3. EU5. Next-Generation Cancer Diagnostics Market Forecast 2017-2027
    • 5.3.1. Germany: Leading Market in the EU
    • 5.3.2. France: Reduction in Healthcare Spending
    • 5.3.3. UK: 100,000 Genomes Project
    • 5.3.4. Spain: Recovering from Financial Crisis
    • 5.3.5. Italy: Decreasing Reimbursement
  • 5.4. Japanese Next-Generation Cancer Diagnostics Market Forecast 2017-2027
    • 5.4.1. Takeda Collaborated with NCC in Genomic Screening Project
    • 5.4.2. Qiagen Partnered Hitachi on PCR and NGS Technologies
    • 5.4.3. Increase Cancer Rates in Fukushima after Nuclear Disaster?
  • 5.5. Chinese Next-Generation Cancer Diagnostics Market Forecast 2017-2027
    • 5.5.1. Illumina Entering the Chinese Market
    • 5.5.2. Epigenomics Colorectal Cancer Test Approved in China
    • 5.5.3. China Offered Free Screenings for Cervical and Breast Cancer
  • 5.6. Indian Next-Generation Cancer Diagnostics Market Forecast 2017-2027
    • 5.6.1. Lack of Genetic Testing Regulation
    • 5.6.2. Cancer Genetics Launched NGS Cancer Panel in India
  • 5.7. Brazilian Next-Generation Cancer Diagnostics Market Forecast 2017-2027
  • 5.8. Russian Next-Generation Cancer Diagnostics Market Forecast 2017-2027
    • 5.8.1. IBM's Collaboration with Russian Companies to Advance Clinical Decision Making

6. Leading Companies in the Next-Generation Cancer Diagnostics Market 2017

  • 6.1. Roche Diagnostics
    • 6.1.1. Roche Diagnostics: Product Portfolio
    • 6.1.2. Roche Diagnostics: Diagnostics Sales Outlook
    • 6.1.3. Cobas HPV Test Approved in the US in 2014
    • 6.1.4. Roche Diagnostics: Recent M&A Activity
    • 6.1.5. Roche Coming Back to the NGS Business?
  • 6.2. Abbott Laboratories
    • 6.2.1. Abbott: Next-Generation Cancer Diagnostics Product Portfolio
    • 6.2.2. Abbott: Diagnostics Sales Outlook
    • 6.2.3. Abbott Obtained Exclusive License for Bladder Cancer Biomarker FGFR3
  • 6.3. Qiagen
    • 6.3.1. Qiagen: Next-Generation Cancer Diagnostics Product Portfolio 2017
    • 6.3.2. Qiagen: Diagnostics Sales Outlook
    • 6.3.3. HalioDx Created from Qiagen Marseille
  • 6.4. Thermo Fisher Scientific
    • 6.4.1. Thermo Fisher Scientific: Business Segments
    • 6.4.2. Thermo Fisher: Next-Generation Cancer Diagnostics Product Portfolio 2015
    • 6.4.3. Thermo Fisher: Life Sciences Outlook
    • 6.4.4. NGS Oncomine Focus Assay for Oncology Research
  • 6.5. Agilent Technologies
    • 6.5.1. Agilent: Next-Generation Cancer Diagnostics Product Portfolio
    • 6.5.2. Agilent: Life Sciences and Diagnostics Sales Outlook
    • 6.5.3. Partnerships and Collaborations for Companion Diagnostics
  • 6.6. Hologic
    • 6.6.1. Hologic: Next-Generation Cancer Diagnostics Product Portfolio
    • 6.6.2. Hologic: Diagnostics Sales Outlook
  • 6.7. Illumina
    • 6.7.1. Illumina: Technology and Product Portfolio
    • 6.7.2. Illumina: Sales Outlook
    • 6.7.3. Illumina: Recent M&A Activity
    • 6.7.4. Joined Forces with UK Government for 100,000 Genomes Project
    • 6.7.5. Partnered with Merck Serono to Develop NGS Cancer Diagnostics
    • 6.7.6. Investing on Synthetic DNA Manufacturing Technology
  • 6.8. Myriad Genetics
    • 6.8.1. Myriad: Next-Generation Cancer Diagnostics Product Portfolio
    • 6.8.2. Myriad: Sales Outlook
    • 6.8.3. New Landscape in the BRCA Diagnostic Market

7. Qualitative Analysis of the Next-Generation Cancer Diagnostics Market 2017-2027

  • 7.1. SWOT Analysis of the Next-Generation Cancer Diagnostics Market
  • 7.2. Strengths
    • 7.2.1. Global Cancer Rates Set to Soar
    • 7.2.2. Increasing Awareness of Molecular Cancer Diagnostics
    • 7.2.3. The Trend in Precision Medicine
  • 7.3. Weaknesses
    • 7.3.1. Industry Facing Increasing Reimbursement Pressure
    • 7.3.2. Physicians' Reliance on Traditional Methods
  • 7.4. Opportunities
    • 7.4.1. Expanding Biomarkers and Cancer Test Menus
    • 7.4.2. Emerging Market to Provide Future Growth
    • 7.4.3. Companion Diagnostics on the Rise
  • 7.5. Threats
    • 7.5.1. Decreasing Healthcare Spending
    • 7.5.2. Gene Patenting Banned in the US?

8. Conclusions

  • 8.1. The World Next-Generation Cancer Diagnostics Market
    • 8.1.1. Current Leading Next-Generation Cancer Diagnostics Segments
    • 8.1.2. Notable Next-Generation Cancer Diagnostics Companies
    • 8.1.3. Leading Regional Markets
    • 8.1.4. World Next-Generation Cancer Diagnostics Market Forecast 2017-2027
  • 8.2. The Future of the Next-Generation Cancer Diagnostics Market
  • Glossary
  • Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Visiongain report evaluation form

List of Figures

  • Figure 1.1: New Cancer Cases and Deaths in More Developed and Less Developed Regions
  • Figure 1.2: Global Next-Generation Cancer Diagnostics Market Segmentation Overview 2017
  • Figure 3.1: Most Common Causes of Cancer Death, 2012
  • Figure 3.2: The Next-Generation Cancer Diagnostics Market: Revenue ($m), AGR (%), 2016-2027
  • Figure 3.3: Market Shares (%) of Leading Next-Generation Cancer Diagnostics Market Segments, 2016
  • Figure 3.4: Market Shares (%) of Leading Next-Generation Cancer Diagnostics Market Segments, 2021
  • Figure 3.5: Market Shares (%) of Leading Next-Generation Cancer Diagnostics Market Segments, 2027
  • Figure 3.6: Next-Generation Cancer Diagnostics: Market Drivers and Restraints 2017-2027
  • Figure 4.1: Advanced PCR Techniques Market: Revenue ($m), AGR (%), 2016-2027
  • Figure 4.2: Advanced PCR-Based Techniques: Drivers and Restraints 2017-2027
  • Figure 4.3: ISH Cancer Diagnostics Market: Revenue ($m), AGR (%), 2016-2027
  • Figure 4.4: ISH Cancer Diagnostics: Drivers and Restraints 2017-2027
  • Figure 4.5: CTCs Analysis Market: Revenue ($m), AGR (%), 2016-2027
  • Figure 4.6: CTCs Analysis: Drivers and Restraints 2017-2027
  • Figure 4.7: Microarray Cancer Diagnostics Market: Revenue ($m), AGR (%), 2016-2027
  • Figure 4.8: Microarray Cancer Diagnostics: Drivers and Restraints 2017-2027
  • Figure 4.9: NGS Cancer Diagnostics Market: Revenue ($m), AGR (%), 2016-2027
  • Figure 4.10: NGS Cancer Diagnostics: Drivers and Restraints 2017-2027
  • Figure 5.1: New Cancer Cases and Deaths in More Developed and Less Developed Regions
  • Figure 5.2: World Next-Generation Cancer Diagnostics Market: Revenues ($m) by Region, 2016-2027
  • Figure 5.3: World Next-Generation Cancer Diagnostics Market: Market Shares (%) by Regional Market, 2016
  • Figure 5.4: World Next-Generation Cancer Diagnostics Market: Market Shares (%) by Regional Market, 2021
  • Figure 5.5: World Next-Generation Cancer Diagnostics Market: Market Shares (%) by Regional Market, 2027
  • Figure 5.6: US Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), 2016-2027
  • Figure 5.7: EU5 Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), 2016-2027
  • Figure 5.8: Japanese Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), 2016-2027
  • Figure 5.9: Chinese Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), 2016-2027
  • Figure 5.10: Indian Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), 2016-2027
  • Figure 5.11: Brazilian Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), 2016-2027
  • Figure 5.12: Russian Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), 2016-2027
  • Figure 6.1: Roche Diagnostics: Revenue Share (%) by Segment, 2016
  • Figure 6.2: Roche Diagnostics: Diagnostics Revenue ($m), AGR (%), 2011-2016
  • Figure 6.3: Roche Diagnostics: Net Sales ($bn) by Region, 2016
  • Figure 6.4: Abbott: Diagnostics Revenue ($m), AGR (%), 2011-2016
  • Figure 6.5: Qiagen: Molecular Diagnostics Revenue ($m), AGR (%), 2011-2016
  • Figure 6.6: Life Technologies: Revenue ($m), AGR (%), 2008-2012
  • Figure 6.7: Agilent: Life Sciences and Diagnostics Revenue ($m), AGR (%), 2011-2016
  • Figure 6.8: Hologic: Diagnostics Revenue ($m), AGR (%), 2011-2016
  • Figure 6.9: Illumina: Revenue Share (%) by Business Segment, 2016
  • Figure 6.10: Illumina: Revenue Share (%) by Geographic Area, 2016
  • Figure 6.11: Illumina: Revenue ($m), AGR (%), 2011-2016
  • Figure 6.12: Myriad: Revenue ($m), AGR (%), 2011-2016

List of Tables

  • Table 1.1: Leading National Next-Generation Cancer Diagnostics Market Forecast 2016-2027 ($m, AGR%, CAGR%)
  • Table 3.1: The Next-Generation Cancer Diagnostics Market: Revenue ($m), AGR (%), CAGR (%), 2017-2027
  • Table 3.2: Selected Biomarkers For Cancer Diagnostics
  • Table 3.3: FDA Approved Nucleic Acid Based Tests
  • Table 3.4: Selected Molecular Diagnostic Tests for Breast Cancer
  • Table 3.5: Selected Molecular Diagnostic Tests for Prostate Cancer
  • Table 3.6: Selected Molecular Diagnostics Test for Colorectal Cancer
  • Table 3.7: Companion Diagnostic Devices Approved by FDA
  • Table 4.1: Advanced PCR Techniques Market: Revenue ($m), AGR (%), CAGR (%), 2016-2027
  • Table 4.2: ISH Cancer Diagnostics Market: Revenue ($m), AGR (%), CAGR (%), 2016-2027
  • Table 4.3: CTCs Analysis Market: Revenue ($m), AGR (%), CAGR (%), 2016-2027
  • Table 4.4: Microarray Cancer Diagnostics Market: Revenue ($m), AGR (%), CAGR (%), 2016-2027
  • Table 4.5: NGS Cancer Diagnostics Market: Revenue ($m), AGR (%), CAGR (%), 2016-2027
  • Table 5.1: World Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), CAGR (%) by Region, 2017-2027
  • Table 5.2: US Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
  • Table 5.3: EU5 Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
  • Table 5.4: Japanese Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
  • Table 5.5: Chinese Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
  • Table 5.6: Indian Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
  • Table 5.7: Brazilian Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
  • Table 5.8: Russian Next-Generation Cancer Diagnostics Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2016-2027
  • Table 6.1: Roche: Overview
  • Table 6.2: Roche Diagnostics: Key Instrument/Device Launches Planned
  • Table 6.3: Roche Diagnostics: Key Test Launches
  • Table 6.4: Roche Diagnostics: Diagnostics Revenue ($m), AGR (%), CAGR (%), 2011-2016
  • Table 6.5: Abbott Laboratories: Overview
  • Table 6.6: Abbott: Diagnostics Revenue ($m), AGR (%), CAGR (%), 2011-2016
  • Table 6.7: Qiagen: Overview
  • Table 6.8: Qiagen: Molecular Diagnostics Revenue ($m), AGR (%), CAGR (%), 2011-2016
  • Table 6.9: Thermo Fisher: Overview
  • Table 6.10: Thermo Fisher: Life Sciences Solutions Segment Revenue ($m), AGR (%), 2012-2015
  • Table 6.11: Life Technologies: Revenue ($m), AGR (%), CAGR (%), 2008-2012
  • Table 6.12: Agilent: Overview
  • Table 6.13: Agilent: Life Sciences and Diagnostics Revenue ($m), AGR (%), CAGR (%), 2011-2016
  • Table 6.14: Hologic: Overview
  • Table 6.15: Hologic: Diagnostics Revenue ($m), AGR (%), CAGR (%), 2011-2016
  • Table 6.16: Illumina: Overview
  • Table 6.17: Illumina: Sequencing Product Portfolio
  • Table 6.18: Illumina: Microarray Product Portfolio
  • Table 6.19: Illumina: Revenue ($m), AGR (%), CAGR (%), 2011-2016
  • Table 6.20: Myriad: Overview
  • Table 6.21: Myriad: Revenue ($m), AGR (%), CAGR (%), 2011-2016
  • Table 7.1: SWOT Analysis of the Next-Generation Cancer Diagnostics Market, 2017-2027

Companies Listed

  • 454 Life Sciences
  • Abbott Laboratories
  • AbbVie
  • AbVitro
  • Advanced Cell Diagnostics
  • Advanced Liquid Logic
  • Affymetrix
  • Agendia
  • Agilent Technologies
  • Ambry
  • Amgen
  • Annoroad
  • Applied Biosystems
  • ARCH Venture Partners
  • AstraZeneca
  • Atossa Genetics
  • AvanSci
  • Aviva Biosciences
  • BD
  • Berry Genomics
  • BGI
  • Bina Technologies
  • Biobase
  • Biochain
  • BioFluidica
  • BioMarin Pharmaceutical
  • bioMérieux
  • Bio-Rad
  • BioServe India
  • BlueGnome
  • Bristol-Myers Squibb
  • Bruker
  • Cancer Genetics
  • Cepheid
  • CLC bio
  • CompanionDx
  • Counsyl
  • Crescendo Bioscience
  • CytoTrack
  • Dako
  • DakoCytomation
  • Danaher
  • DiagnoCure
  • DxS
  • Eli Lilly
  • Enzymatics
  • Epic Sciences
  • Epicentre Technologies
  • Epigenomics
  • Exact Sciences
  • Fidelity Management
  • Fluidigm
  • Fluxion
  • GeneDx
  • Genentech
  • Genia Technologies
  • Genomic Health
  • Gen-Probe
  • GnuBio
  • HalioDX
  • Hitachi High-Technologies
  • Hologic
  • Idaho Technology
  • IGEN International
  • Illumina
  • Ingenuity Systems
  • Insilico Medicine
  • Invitae
  • Invitrogen
  • Ipsogen
  • Iquum
  • Iris Molecular Diagnostics
  • Janssen Biotech
  • Janssen Diagnostics
  • LabCorp
  • Life Technologies
  • Luminex Corporation
  • Manostring Technologies
  • Merck
  • Miltenyi Biotec
  • Mylan
  • Myraqa
  • Myriad Genetics
  • NextBio
  • Oncolys BioPharma
  • Ono Pharmaceutical
  • Oxford Nanopore
  • Pacific Biosciences
  • Pathway Genomics
  • Pathway Pharmaceuticals
  • Pensabio
  • PerkinElmer
  • Pfizer
  • Prosigna
  • Qiagen
  • Qiagen Marseille
  • Quest Diagnostics
  • Quidel
  • RainDance Technologies
  • Rarecells
  • Roche Diagnostics
  • Sakura
  • Sanofi
  • ScreenCell
  • Siemens
  • Signature Diagnostics
  • Silicon Biosystems
  • SRI Biosciences
  • Stratos Genomics
  • Sysmex
  • Takeda
  • Thermo Fisher Scientific
  • Twist Bioscience
  • Ventana Medical Systems
  • Verinata Health
  • Vysis

List of Organizations Mentioned in the Report

  • Actionable Genome Consortium
  • Arizona State University
  • Carnegie Mellon University
  • First Oncology Research and Advisory Center
  • Genomics England
  • Institut Curie
  • MGH Cancer Center
  • Massachusetts Institute of Technology
  • National Cancer Center
  • Paris-Descartes University
  • Pennsylvania State University
Back to Top